An anti-vomiting medication for post-operative patients has smashed its phase III trial in the UK in one of the largest ever post-operation-nausea studies…ever. Roll on FDA approval.
Acacia Pharma is a Cambridge based clinical-stage biotech which looks to provide supportive care of patients with debilitating conditions arising as a consequence of surgery, cancer or cancer treatment.
One such angle of care involves reducing the nausea experienced after a patient goes through surgery, or the compulsive need to vomit when undergoing chemotherapy – both of which can have a dramatic toll on quality of life for patients. Acacia’s phase III trials for an anti-emetic, Baremsis, has therefore been offered as a potential preventative for such symptoms.
Currently two classes of anti-emetics are predominantly used to prevent post-operative nausea and vomiting (PONV) in these patients which is associated with the use of anaesthetic gases and opioid pain-killers (affecting up to 80% of high-risk patients).